MedTrace Logo

Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease

NCT03297515 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-02-23

No results posted yet for this study

Summary

Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.

Conditions

  • Dry AMD
  • Stargardt Disease 1

Interventions

DIETARY_SUPPLEMENT

Madeos

Arm 1: Omega 3

DIETARY_SUPPLEMENT

Placebo

Arm 2 : Placebo

Sponsors & Collaborators

  • Ophthalmos Research and Education Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2020-09-22
Completion
2020-09-22

Countries

  • France
  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03297515 on ClinicalTrials.gov